Maternal Intrahepatic Cholestasis: What Ursodeoxycholic Acid Can Do

Maternal intrahepatic cholestasis is a pregnancy-specific liver disorder characterised by itching, raised serum bile acids and, often, abnormal liver function tests. The itch commonly affects the palms and soles, may be worse at night, and can occur without a visible rash. Although symptoms usually settle after birth, the condition matters because bile acid concentration is associated with fetal risk, particularly later in pregnancy.

Ursodeoxycholic acid, also called ursodiol or UDCA, is widely used to relieve maternal symptoms and improve biochemical test results. Its role in preventing stillbirth, spontaneous preterm birth or neonatal complications is less certain. Current evidence supports a careful, individualised approach rather than presenting the medicine as a complete solution.

For Australian families, management can involve a GP, obstetrician, midwife, hepatology team, pathology service and tertiary maternity unit. Care may look different in a metropolitan hospital such as the Royal Women’s Hospital in Melbourne than in a remote community where repeat blood tests and transfer planning require extra time.

Understanding The Condition

Intrahepatic cholestasis of pregnancy, or ICP, develops when bile flow from the liver becomes impaired during pregnancy. Hormonal, genetic and environmental factors may contribute. A patient may report intense pruritus before blood tests become abnormal, so a normal first test does not always exclude the diagnosis. Repeating bile acids and liver function tests is appropriate when symptoms continue.

Bile acid concentration is the key marker used to classify risk. Levels can fluctuate, and results may rise after a period of itching. Many guidelines distinguish mild disease from more severe disease at thresholds such as 40 and 100 micromol/L, although terminology and recommended management vary. Other causes of itching or liver dysfunction, including viral hepatitis, gallstones, drug-related injury and pre-eclampsia, need to be considered.

Australian clinicians commonly coordinate testing through local pathology networks, with samples reviewed alongside gestational age, medical history and fetal wellbeing. A patient in regional Queensland, Western Australia or the Northern Territory may need a longer trip for specialist review than someone living near a major women’s hospital. That practical reality belongs in the care plan from the first abnormal result.

What Ursodeoxycholic Acid Changes

UDCA is a naturally occurring bile acid with effects on bile composition and transport. In ICP, it may reduce the concentration of more harmful bile acids and improve liver enzyme results. Some patients experience less itching within days or weeks, although the response is variable and symptom relief is often incomplete.

The best-known large randomised trial, PITCHES, found that UDCA produced a small reduction in itch and did not significantly reduce a composite of adverse perinatal outcomes. It also did not establish a meaningful reduction in stillbirth or neonatal intensive care admission. These findings changed how specialists describe the medicine: it can be a reasonable treatment for maternal symptoms, but it should not be promised as fetal protection.

Treatment is generally prescribed by weight, with the dose adjusted according to symptoms, bile acid trends and local protocol. Side effects can include diarrhoea, nausea or abdominal discomfort. Self-starting a product bought online is inappropriate because the diagnosis, formulation, dose and monitoring all matter. In Australia, a hospital pharmacy or community pharmacy may dispense the medicine under a prescription, depending on the care setting and availability.

Evidence From Perinatal Practice

The evidence around UDCA is sometimes oversimplified in online discussions. Improved blood tests may look reassuring, yet biochemical improvement does not necessarily translate into a lower risk of stillbirth. Fetal risk appears to be more closely associated with the highest recorded bile acid level than with whether a medication has normalised a later sample.

For that reason, treatment usually combines symptom management with a plan for repeat blood tests, obstetric review and delivery timing. Some services offer antenatal corticosteroids when early birth is anticipated. Fetal monitoring may be used, but a normal cardiotocograph or ultrasound cannot reliably predict or prevent every sudden complication linked with ICP.

The wider perinatal context also matters. Multiple pregnancy, diabetes, hypertension, fetal growth concerns and previous obstetric complications can alter the balance of risks. Research discussed in the multiple gestation evidence resource illustrates why maternal and neonatal outcomes should be assessed together rather than reduced to a single laboratory number.

Timing Birth And Monitoring

Decisions about birth are usually based on the peak bile acid concentration, the clinical picture and the availability of safe neonatal care. In many international recommendations, bile acids of 100 micromol/L or more lead to discussion of planned birth around 35 to 36 weeks, while lower concentrations may allow later delivery if results remain stable. Australian hospitals may use slightly different thresholds or timing, so local specialist guidance is essential.

Induction of labour may be offered when the benefits of avoiding continued pregnancy outweigh the risks of earlier birth. The discussion should cover cervical readiness, previous caesarean birth, fetal maturity and the capacity of the local unit to provide newborn respiratory support. For a family travelling from country Victoria or far north Queensland, the plan may include accommodation near the hospital before the recommended birth window.

Monitoring often includes repeated bile acids and liver function tests. Patients should report reduced fetal movements immediately through their maternity service rather than waiting for the next appointment. Itching itself is distressing but does not provide a reliable measure of fetal wellbeing, and symptom improvement after UDCA should not be used as a reason to postpone a planned review.

Australian Care Considerations

Australia has a mixed public and private maternity system. A patient in a public tertiary unit may see a rotating medical team, while someone in private care may have a regular obstetrician but still require referral to a larger hospital if early birth or neonatal support is likely. RANZCOG guidance, hospital protocols and specialist judgement can therefore influence the practical details of care.

Medication access is usually straightforward in capital cities, but rural and remote patients may face delays with pathology turnaround, pharmacy supply or travel. Health professionals can reduce disruption by arranging repeat testing before appointments, explaining which symptoms require urgent contact and confirming where prescriptions can be filled. Clear written plans are particularly useful when a patient moves between a GP clinic, local maternity ward and tertiary centre.

Language also shapes communication. Australian families may casually refer to the baby as a “bub”, yet discussions still need precise terms such as peak bile acids, gestational age and planned birth date. Interpreter support should be offered when required. Aboriginal and Torres Strait Islander patients may prefer care that involves Aboriginal health workers, family networks and culturally safe services, with transfer decisions made collaboratively wherever possible.

The history of international perinatal collaboration provides useful context for this work. The FAOPS 2020 archive records a planned Tokyo congress focused on perinatal and neonatal medicine that was cancelled in April 2020 because of COVID-19 and travel restrictions. Its subject area reflects the same need for collaboration that continues today: evidence must be translated into care that works across different hospitals, populations and distances.

Counselling Families About UDCA

A balanced conversation starts by separating maternal benefit from fetal benefit. A clinician can explain that UDCA may make itching more manageable and may improve bile acid or liver test results, while also stating that it has not been shown to eliminate the risk of stillbirth. This phrasing avoids false reassurance without dismissing a treatment that may improve daily life during pregnancy.

It is also important to discuss sleep, skin care and safe options for additional symptom relief. Sedating antihistamines may help some patients sleep, but they do not treat the underlying cholestasis and should be recommended by a clinician familiar with the pregnancy. New rashes, jaundice, dark urine, pale stools or severe abdominal pain warrant assessment for another liver or pregnancy-related condition.

After birth, itching and bile acids generally improve, but follow-up liver tests are advisable if symptoms persist or results remain abnormal. Recurrence in a future pregnancy is common, so early disclosure of the history allows prompt testing. Hormonal contraception and other liver conditions can require individual discussion after delivery.

The most useful message is practical: take UDCA exactly as prescribed, attend repeat testing, follow the agreed birth plan and seek urgent assessment for reduced movements or concerning symptoms. By combining medication with surveillance and timely obstetric decision-making, maternity teams can support the pregnant patient while keeping the baby’s changing risk profile at the centre of care.

Clinicians and families can use current local protocols, specialist review and reliable perinatal research to build an individual plan for ICP. UDCA has a place in that plan, particularly for maternal symptoms, but its effectiveness should be judged alongside bile acid trends, gestational age, fetal assessment and safe access to the right level of maternity care.